tbuckley/cabot-search huggingface dataset:
Activation of complement component 3 is associated with airways disease and pulmonary emphysema in alpha-1 antitrypsin deficiency
Authors: Michael E O'Brien, Laura Fee, Niall Browne, Tomás P Carroll, Paula Meleady, Michael Henry, Karen McQuillan, Mark P Murphy, Mark Logan, Cormac McCarthy, Oliver J McElvaney, Emer P Reeves, Noel G McElvaney
Journal: Thorax (2020)

Alpha-1 antitrypsin (AAT) deficiency (AATD) is associated with early onset emphysema. The aim of this study was to investigate whether AAT binding to plasma constituents could regulate their activation, and in AATD, exploit this binding event to better understand the condition and uncover novel biomarkers of therapeutic efficacy.To isolate AAT linker proteins, plasma samples were separated by size exclusion chromatography, followed by co-immunoprecipitation. AAT binding proteins were identified by mass spectrometry. Complement turnover and activation was determined by ELISA measurement of C3, C3a and C3d levels in plasma of healthy controls (n=15), AATD (n=51), non-AATD patients with obstructive airway disease (n=10) and AATD patients post AAT augmentation therapy (n=5).Direct binding of complement C3 to AAT was identified in vivo and in vitro. Compared with healthy controls, a breakdown product of C3, C3d, was increased in AATD (0.04 µg/mL vs 1.96 µg/mL, p=0.0002), with a significant correlation between radiographic pulmonary emphysema and plasma levels of C3d (R2=0.37, p=0.001). In vivo, AAT augmentation therapy significantly reduced plasma levels of C3d in comparison to patients not receiving AAT therapy (0.15 µg/mL vs 2.18 µg/mL, respectively, p=0.001).Results highlight the immune-modulatory impact of AAT on the complement system, involving an important potential role for complement activation in disease pathogenesis in AATD. The association between plasma C3d levels and pulmonary disease severity, that decrease in response to AAT augmentation therapy, supports the exploration of C3d as a candidate biomarker of therapeutic efficacy in AATD.
High Expression of Macrophage Stimulating Protein (MSP) Correlates with Survival Benefit in Malignant Pleural Mesothelioma
Authors: D. Easty, A. Baird, K.J. O'Byrne, A. Soltermann, D. Nonaka, D. Fennell, L. Mutti, H.I. Pass, I. Opitz, S.G. Gray
Journal: Annals of Oncology (2012)
Met as Prognostic Factor and Therapeutic Target in Pretreated Hepatocellular Carcinoma (HCC): Final Results of a Randomized Controlled Phase 2 Trial (RCT) with Tivantinib (ARQ 197)
Authors: B. Daniele, L. Rimassa, C. Porta, I. Borbath, S. Salvagni, J. van Laethem, H. van Vlierberghe, R. von Roemeling, G. Abbadessa, A. Santoro
Journal: Annals of Oncology (2012)
Plasma Level of Des-Acyl Ghrelin Predicts Digestive Symptoms in Patients Undergoing Chemotherapy for Advanced Pancreatic Cancer
Authors: T. Miura, S. Mitsunaga, N. Matsumoto, M. Nakazato, I. Ohno, S. Shimizu, H. Takahashi, H. Okuyama, A. Kuwahara, M. Ikeda
Journal: Annals of Oncology (2012)
Diagnostic performance of different cholangioscopes in patients with biliary strictures: a systematic review
Authors: Santi Kulpatcharapong, Rapat Pittayanon, Stephen J. Kerr, Rungsun Rerknimitr
Journal: Endoscopy (2020)

Abstract Background Cholangioscopy provides direct intraductual imaging, which can enhance diagnostic efficacy during endoscopic retrograde cholangiopancreatography in patients with biliary strictures. This study aimed to review the diagnostic yield of different cholangioscopes for the diagnosis of malignant biliary stricture (MBS). Methods A comprehensive literature review was performed. Full papers of prospective studies using any type of peroral cholangioscope (POC) were included without language restriction. The primary outcomes were sensitivity, specificity, and accuracy of various POCs to diagnose MBS. Results Data from 20 published articles, involving 1141 patients, were extracted. Overall sensitivities of POCs for diagnosing MBS were higher for the diagnosis made under visual impression compared with those from cholangioscopy-guided biopsy (67 % – 100 % vs. 38 % – 100 %), whereas the overall specificities were generally high and comparable (73 % – 100 % vs. 75 % – 100 %). Newer video cholangioscopes (digital single-operator POC [digital SOC], direct POC) with the exception of video dual-operator mother – baby POC (video DOC), provided better sensitivity of cholangioscopy-guided biopsy compared with fiberoptic scopes (digital SOC 80 % – 85 %, direct POC 80 % – 100 %, video DOC 38 % – 100 %, and fiberoptic SOC 49 % – 100 %, respectively). Among these video cholangioscopes, the digital SOC provided the highest technical success rate, at 100 %. Conclusions POCs enhanced the diagnostic yield for diagnosis of MBS. Compared with fiberoptic POCs that only provide good image impression, the digital SOC and direct POC were good at both image impression and cholangioscopy-guided biopsy to diagnose MBS. To ensure high technical success for MBS diagnosis, the digital SOC is a good option.
Monitoring of Metastatic Breast Cancer Using Circulating Tumour DNA: A Comparison With Circulating Tumour Cells
Authors: S. Dawson, D. Tsui, M. Murtaza, H. Biggs, S. Chin, D. Gale, T. Forshew, M. Wallis, N. Rosenfeld, C. Caldas
Journal: Annals of Oncology (2012)
Analysis of the Association Between the Number of Regimens and the Frequency of Side Effects in Outpatients Receiving Cancer Chemotherapy. Can Progression-Free Survival be the Primary End Point?
Authors: T. Kushihara, K. Kawada, H. Kushihara, N. Hamajima, M. Amano, K. Ooji, K. Honda, F. Nomura, Y. Ikeda, K. Mori
Journal: Annals of Oncology (2012)
Ph Ib/Ii Study Of BKM120 Plus Trastuzumab (T) in Patients With T-resistant HER2+ Advanced Breast Cancer (BC)
Authors: B. Pistilli, A. Urruticoechea, S. Chan, H.S. Han, G. Jerusalem, A. Kong, Q. Ru, S. Ruquet, D.W. Sternberg, C. Saura
Journal: Annals of Oncology (2012)
Correction: The acetyltransferase GCN5 maintains ATRA-resistance in non-APL AML
Authors: Melanie Kahl, Annamaria Brioli, Martin Bens, Florian Perner, Anne Kresinsky, Ulf Schnetzke, Anna Hinze, Yordan Sbirkov, Sven Stengel, Giorgia Simonetti, Giovanni Martinelli, Kevin Petrie, Arthur Zelent, Frank-Dietmar Böhmer, Marco Groth, Thomas Ernst, Florian H. Heidel, Sebastian Scholl, Andreas Hochhaus, Tino Schenk
Journal: Leukemia (2020)
P-0127 Study on 34 Cases with Primary Malignant Gastric Lymphoma
Authors: Kazuhiko Natori, Susumu Ishihara, Daisuke Nagase, Akiko Shibuya, Yukitoshi Toyoda, Yoshinori Fujimoto, Yasunobu Kuraishi, Kazutoshi Shibuya, Haruka Izumi
Journal: Annals of Oncology (2012)
Correlation of C609T Polymorphism of Nadph Quinone Oxidoreductase 1 and Hematological Toxicities in Lung Cancer Patients Treated With Amrubicin
Authors: M. Nagata, T. Kimura, T. Suzumura, S. Kudoh, K. Umekawa, Y. Kira, K. Matsuura, T. Nakai, S. Mitsuoka, K. Hirata
Journal: Annals of Oncology (2012)
Long-term results of a randomized clinical trial comparing endoscopic versus conventional treatment of pilonidal sinus
Authors: Marco Milone, Nunzio Velotti, Michele Manigrasso, Sara Vertaldi, Katia Di Lauro, Giuseppe De Simone, Vera Cirillo, Francesco Maione, Nicola Gennarelli, Loredana Maria Sosa Fernandez, Giovanni Domenico De Palma
Journal: International Journal of Surgery (2020)
Complaints: only 38% of hospitals in England report any action taken in response
Authors: Elisabeth Mahase
Journal: BMJ (2020)

Just over a third (38%) of NHS hospitals in England reported on any action taken in response to complaints raised by patients or loved ones in 2018, research has shown.

A review of complaint reporting, carried out by Healthwatch,1 found that just one in eight hospital trusts had provided all necessary information to comply with statutory complaint regulations.

The review team searched through 149 NHS acute trust websites and found that, while all hospitals reported the number of complaints that they had received, just 16% of hospitals published the required standalone complaint reports.

In other publicly available sources, such as annual accounts, hospitals often reported that …
Autologous Stem Cell Transplantation for Higher-Risk Diffuse Large B-Cell Lymphoma in the First Remission
Authors: H. Kaneko, Y. Tsutsumi, T. Iwai, T. Kobayashi, Y. Matsumoto, J. Kuroda, S. Horiike, S. Yokota, M. Taniwaki
Journal: Annals of Oncology (2012)
Astrocyte Unfolded Protein Response Induces a Specific Reactivity State that Causes Non-Cell-Autonomous Neuronal Degeneration
Authors: Heather L. Smith, Oliver J. Freeman, Adrian J. Butcher, Staffan Holmqvist, Ibrahim Humoud, Tobias Schätzl, Daniel T. Hughes, Nicholas C. Verity, Dean P. Swinden, Joseph Hayes, Lis de Weerd, David H. Rowitch, Robin J.M. Franklin, Giovanna R. Mallucci
Journal: Neuron (2020)

Recent interest in astrocyte activation states has raised the fundamental question of how these cells, normally essential for synapse and neuronal maintenance, become pathogenic. Here, we show that activation of the unfolded protein response (UPR), specifically phosphorylated protein kinase R-like endoplasmic reticulum (ER) kinase (PERK-P) signaling-a pathway that is widely dysregulated in neurodegenerative diseases-generates a distinct reactivity state in astrocytes that alters the astrocytic secretome, leading to loss of synaptogenic function in vitro. Further, we establish that the same PERK-P-dependent astrocyte reactivity state is harmful to neurons in vivo in mice with prion neurodegeneration. Critically, targeting this signaling exclusively in astrocytes during prion disease is alone sufficient to prevent neuronal loss and significantly prolongs survival. Thus, the astrocyte reactivity state resulting from UPR over-activation is a distinct pathogenic mechanism that can by itself be effectively targeted for neuroprotection.
Survival Among Metastatic Colorectal Cancer (MCRC) Patients Treated in a Randomized Controlled Trial (RCT) vs an Observational Cohort Study (OCS)
Authors: S.Y. Zafar, A. Grothey, T. Bekaii-Saab, J. Bendell, B. Sherrill, L. Bennett, Y. Mun, M. Sersch, D. Dalal, H.I. Hurwitz
Journal: Annals of Oncology (2012)
Phospho‐Profiling Linking Biology and Clinics in Pediatric Acute Myeloid Leukemia
Authors: Angela Schumich, Michaela Prchal‐Murphy, Margarita Maurer‐Granofszky, Andrea Hoelbl‐Kovacic, Nora Mühlegger, Ulrike Pötschger, Sabine Fajmann, Oskar A. Haas, Karin Nebral, Nils von Neuhoff, Martin Zimmermann, Heidrun Boztug, Mareike Rasche, Marlies Dolezal, Christiane Walter, Dirk Reinhardt, Veronika Sexl, Michael N. Dworzak
Journal: HemaSphere (2019)

Aberrant activation of key signaling-molecules is a hallmark of acute myeloid leukemia (AML) and may have prognostic and therapeutic implications. AML summarizes several disease entities with a variety of genetic subtypes. A comprehensive model spanning from signal activation patterns in major genetic subtypes of pediatric AML (pedAML) to outcome prediction and pre-clinical response to signaling inhibitors has not yet been provided. We established a high-throughput flow-cytometry based method to assess activation of hallmark phospho-proteins (phospho-flow) in 166 bone-marrow derived pedAML samples under basal and cytokine stimulated conditions. We correlated levels of activated phospho-proteins at diagnosis with relapse incidence in intermediate (IR) and high risk (HR) subtypes. In parallel, we screened a set of signaling inhibitors for their efficacy against primary AML blasts in a flow-cytometry based ex vivo cytotoxicity assay and validated the results in a murine xenograft model. Certain phospho-signal patterns differ between genetic subtypes of pedAML. Some are consistently seen through all AML subtypes such as pSTAT5. In IR/HR subtypes high levels of GM-CSF stimulated pSTAT5 and low levels of unstimulated pJNK correlated with increased relapse risk overall. Combination of GM-CSF/pSTAT5high and basal/pJNKlow separated three risk groups among IR/HR subtypes. Out of 10 tested signaling inhibitors, midostaurin most effectively affected AML blasts and simultaneously blocked phosphorylation of multiple proteins, including STAT5. In a mouse xenograft model of KMT2A-rearranged pedAML, midostaurin significantly prolonged disease latency. Our study demonstrates the applicability of phospho-flow for relapse-risk assessment in pedAML, whereas functional phenotype-driven ex vivo testing of signaling inhibitors may allow individualized therapy.
Array CGH and DNA Sequencing to Personalize Therapy for Metastatic Breast Cancer: A Prospective National Trial (UNICANCER SAFIR-01)
Authors: F. André, T. Bachelot, M. Campone, M. Arnedos Ballester, F. Commo, A. Gonçalves, C. Levy, J. Ferrero, L. Lacroix, V. Diéras, F. Dalenc, D. Gentien, M. Lacroix, Q. Wang, J. Adelaide, M. Jimenez, H. Bonnefoi
Journal: Annals of Oncology (2012)
Survival Outcomes in Metastatic Colorectal Cancer (CRC) with High-Level Microsatellite Instability (MSI-H)
Authors: M.J. Overman, S. Kopetz, S. Wong, J. Tie, S. Kosmider, A. Jacob, E. Vilar, P. Gibbs, J. Desai, B. Tran
Journal: Annals of Oncology (2012)
Early Data from a Phase I Study of Nintedanib (BIBF 1120) in Asian Patients with advanced Hepatocellular Carcinoma
Authors: C. Yen, Y. Shen, H. Shiah, J. Chen, C. Hsu, C. Hsu, D.C. Huang, J. Hocke, W. Su, A. Cheng
Journal: Annals of Oncology (2012)
RELATION OF LEFT VENTRICULAR DYSSYNCHRONY BY PHASE ANALYSIS OF GATED SPECT IMAGES AND CARDIOVASCULAR EVENTS IN PATIENTS WITH IMPLANTABLE CARDIAC DEFIBRILLATORS.
Authors: Wael AlJaroudi, Fadi Hage, Daniel Hermann, Harrish Doppalapudi, Jaekyeong Heo, Ami E. Iskandrian
Journal: Journal of the American College of Cardiology (2010)
Moving towards clean cooking in China
Authors: Renjie Chen, Haidong Kan
Journal: The Lancet Global Health (2020)

Domestic use of solid fuels is a major source of household air pollution and a substantial contributor to ambient air pollution, particularly in developing global regions. Solid fuel use can increase risks for many cardiopulmonary diseases; in the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017, household air pollution from solid fuel use was estimated to account for about 1·6 million deaths,1 and this number could be underestimated in areas with a high prevalence of solid fuel use.
Predictors of Noncompletion of Cancer Treatments in Elderly Patients: the Elderly Cancer Patients (Elcapa) Cohort Study
Authors: M. Laurent, E. Paillaud, M. Carvalho-Verlinde, P. Caillet, A. Le Thuaut, E. Liuu, S. Bastuji-Garin, S. Culine, F. Canouï-Poitrine
Journal: Annals of Oncology (2012)
Leucine-Rich and Immunoglobulin-Like Domains Germline Polymorphisms Predict Clinical outcome in Metastatic Colorectal Cancer
Authors: D. Páez, A. Sebio Garcia, L. Paré, J. Salazar Blanco, M. Martín-Richard, M. Tobeña Puyal, A. Barnadas, M. Baiget
Journal: Annals of Oncology (2012)
Recommendations Related to Genetic Testing for Breast Cancer
Authors: Thilo Dörk, Tjoung-Won Park-Simon, Peter Hillemanns
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Analysis of Pericarditis Carcinomatosa in our Hospital
Authors: T. Matsumoto, S. Ogawa, K. Takashima, K. Masuo, M. Fukushima, M. Wada, N. Shimeno, S. Inoue, H. Tei, M. Fujita, Y. Suginoshita, A. Okada, T. Inokuma
Journal: Annals of Oncology (2012)
Preliminary Results of Phase I Combination Study of Eribulin Mesylate with Trastuzumab in Patients with Human Epidermal Growth Factor 2 (HER2) Positive Advanced or Metastatic Breast Cancer
Authors: Y. Sasaki, K. Miwa, K. Araki, N. Matsubara, Y. Naito, H. Obaishi, M. Namiki, K. Ishikawa, H. Mukai
Journal: Annals of Oncology (2012)
Response to: ‘Efficacy and improved tolerability of combination therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chester disease’ by Campochiaro <i>et al</i>
Authors: Fleur Cohen-Aubart, Neila Benameur, Zahir Amoura, Julien Haroche
Journal: Annals of the Rheumatic Diseases (2020)

We read with interest the letter by Campochiaro et al 1 that reported the efficacy of a combination regimen including anakinra and targeted therapy for the treatment of Erdheim-Chester disease (ECD), a rare multisystem inflammatory histiocytosis. Based on the involvement of inflammatory cytokines, including tumour necrosis factor-alpha and interleukin-1, in the pathophysiology and the clinical manifestations of ECD, previous reports demonstrated a variable efficacy with a good tolerance of daily subcutaneous anakinra and infliximab for the treatment of ECD.2 3 Among 262 patients with ECD who have been seen at our institution until 2019, 31 (12%) (including 12 described in a previous analysis2) were treated with 100 mg (n=27) or 200 mg (n=4) daily of anakinra, with a mean duration of 29 months (range, 1–132). Patients were followed on a regular basis and evaluated as previously described.4 The clinical and molecular details are provided in table 1. Patients treated with anakinra had more osseous and less central nervous system (CNS) involvements. The patients were treated with anakinra alone or in combination with steroids in two patients, and interferon-alpha in one patient. In the …
Predictive Diagnostics for Response to Therapy of Chemotherapy Associated Anemia with Darbepoetin Alfa +/- Intravenous Iron in Cancer Patients: PFAD-3 a Multicentre Cohort Study in Outpatients
Authors: H.T. Steinmetz, K. Kuhr, M. Hellmich, M. Heinz, M. Neise, J. Mittermüller, H.W. Tessen, M. Reiser, K. Severin, S. Schmitz
Journal: Annals of Oncology (2012)
Clinical efficacy of complement C5a inhibition by IFX‐1 in hidradenitis suppurativa: an open‐label single‐arm trial in patients not eligible for adalimumab
Authors: E.J. Giamarellos‐Bourboulis, M. Argyropoulou, T. Kanni, T. Spyridopoulos, I. Otto, O. Zenker, R. Guo, N.C. Riedemann
Journal: British Journal of Dermatology (2020)
CD Maps - Dynamic Profiling of CD1 to CD100 Surface Expression on Human Leukocyte and Lymphocyte Subsets
Authors: Karel Fišer, Tomas Kalina, Martin Perez-Andres, Daniela Kužílková, Pablo Engel, Marta Cuenca, Elena Blanco Álvarez, Sophinus J.W. Bartol, Menno C. van Zelm
Journal: Blood (2019)
High-Dose Vitamin D Supplementation and Bone Health—Reply
Authors: David A. Hanley, Lauren A. Burt, Steven K. Boyd
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
John Bernard Michael Roberts
Authors: Nadia Roberts
Journal: BMJ (2020)

A Leeds graduate, John Bernard Michael Roberts (“Michael”) started work at Leeds General Infirmary. There he met Jill Foster, a theatre sister, whom he married in 1953. He went into the army to do his national service in Dorchester. They then returned to Leeds before moving to Sheffield before taking up a registrar post at Southmead Hospital in Bristol. In 1966 he started his first consultant post in urology at the Bristol Royal Infirmary. He …
Safety and Pharmacokinetic Evaluation of Repeated Dosing of Palonosetron in Patients Receiving High or Moderate Emetic Risk Chemotherapy
Authors: Y. Ikari, Y. Nakashima, E. Sato, H. Katsuya, T. Goto, M. Ishizu, T. Tanaka, K. Ogata, K. Isutuka, Y. Takamatu, K. Tamura
Journal: Annals of Oncology (2012)
Prognosis of Adenosquamous Carcinoma of the Pancreas: A Matched Case-Control Study
Authors: H. Imaoka, K. Yamao, S. Hijioka, K. Hara, N. Mizuno, T. Tanaka, S. Kondo, M. Tajika, T. Ogura, T. Obayashi, Y. Shimizu, Y. Niwa
Journal: Annals of Oncology (2012)
Prospective multicentre study of rectal carriage of multidrug-resistant Enterobacteriaceae among health-care workers in Spain
Authors: A. Fernández-Verdugo, L. Forcelledo, J. Rodríguez-Lozano, C. Rodríguez-Lucas, L. Barreiro-Hurlé, A. Canut, P. de la Iglesia, D. Escudero, J. Calvo, J.A. Boga, M. Margolles, M.R. Rodicio, J. Fernández
Journal: Clinical Microbiology and Infection (2020)
Clinical Activity and Safety of Anti-Programmed Death-1 (PD-1) (BMS-936558/MDX-1106/ONO-4538) in Patients (PTS) with Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: S. Gettinger, L. Horn, S.J. Antonia, D. Spigel, L. Gandhi, L.V. Sequist, J.M. Wigginton, G. Kollia, A. Gupta, J.R. Brahmer
Journal: Annals of Oncology (2012)
Learning Curve in Robot-assisted Kidney Transplantation: Results from the European Robotic Urological Society Working Group
Authors: Andrea Gallioli, Angelo Territo, Romain Boissier, Riccardo Campi, Graziano Vignolini, Mireia Musquera, Antonio Alcaraz, Karel Decaestecker, Volkan Tugcu, Davide Vanacore, Sergio Serni, Alberto Breda
Journal: European Urology (2020)
PD-0007 18F-Fdg Positron Emission Tomography (FDG-PET) and Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer
Authors: Encarnación González-Flores, Julia Ruiz, Beatriz Gonzalez-Astorga, Verónica Conde, Javier Garcia Garcia, Aranzazu Gonzalez-Vicente, Jesus Soberino, Cynthia Gonzalez, Luque-Caro Raquel, Carmen Sanchez-Toro, Joaquina Martinez-Galan, Juan Ramón Delgado
Journal: Annals of Oncology (2012)